Search hospitals > California > Orange

New Jersey Medical School Clinical Research Center CRS

Claim this profile
Orange, California 92868
Global Leader in Human Immunodeficiency Virus Infection
Global Leader in Infections
Conducts research for HIV
Conducts research for Syndrome
Conducts research for Irritable Bowel Syndrome
93 reported clinical trials
0 medical researchers
Photo of New Jersey Medical School Clinical Research Center CRS in OrangePhoto of New Jersey Medical School Clinical Research Center CRS in OrangePhoto of New Jersey Medical School Clinical Research Center CRS in Orange

Summary

New Jersey Medical School Clinical Research Center CRS is a medical facility located in Orange, California. This center is recognized for care of Human Immunodeficiency Virus Infection, Infections, HIV, Syndrome, Irritable Bowel Syndrome and other specialties. New Jersey Medical School Clinical Research Center CRS is involved with conducting 93 clinical trials across 73 conditions. There are 0 research doctors associated with this hospital, such as .

Area of expertise

1Human Immunodeficiency Virus Infection
Global Leader
New Jersey Medical School Clinical Research Center CRS has run 27 trials for Human Immunodeficiency Virus Infection. Some of their research focus areas include:
HBeAg positive
HBeAg negative
2Infections
Global Leader
New Jersey Medical School Clinical Research Center CRS has run 12 trials for Infections.

Top PIs

Clinical Trials running at New Jersey Medical School Clinical Research Center CRS

Human Immunodeficiency Virus Infection
Prostate Cancer
HIV
HIV/AIDS
Contagious Diseases
HIV Infection
Infections
AIDS
Hepatitis A
Chronic Hepatitis B
Image of trial facility.

IL-15 Superagonist + Antibodies

for HIV/AIDS

The purpose of this study is to evaluate the safety, tolerability, and efficacy of N-803, an IL-15 superagonist, with or without combination broadly neutralizing antibodies (bNAbs), to induce HIV-1 control during analytic treatment interruption (ATI).
Recruiting1 award Phase 116 criteria
Image of trial facility.

Monoclonal Antibodies + ART

for HIV Infection

A5388 is a phase II, two-arm, randomized, double-blind, placebo-controlled study that will enroll 48 antiretroviral therapy (ART)-naïve adults with acute HIV infection (AHI) in order to determine whether: * Administration of combination HIV-specific broadly neutralizing antibody (bNAb) therapy in addition to ART during acute HIV infection (AHI) will be safe. * Participants who receive combination bNAb therapy in addition to ART during AHI will be more likely to demonstrate a delay in time to HIV-1 RNA ≥1,000 copies/mL for 4 consecutive weeks compared to participants who receive placebo plus ART. * Participants who receive combination bNAb therapy in addition to ART during AHI will demonstrate lower viral reservoirs and enhanced HIV-specific immunity compared to participants who receive placebo plus ART.
Recruiting0 awards Phase 2
Image of trial facility.

Selgantolimod

for Chronic Hepatitis B and HIV

This trial tests a pill called Selgantolimod in patients with chronic hepatitis B and HIV who have been on antiviral therapy for an extended period. The pill aims to activate the immune system to reduce the hepatitis B virus levels in their blood.
Recruiting0 awards Phase 2

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at New Jersey Medical School Clinical Research Center CRS?
New Jersey Medical School Clinical Research Center CRS is a medical facility located in Orange, California. This center is recognized for care of Human Immunodeficiency Virus Infection, Infections, HIV, Syndrome, Irritable Bowel Syndrome and other specialties. New Jersey Medical School Clinical Research Center CRS is involved with conducting 93 clinical trials across 73 conditions. There are 0 research doctors associated with this hospital, such as .